- PR Newswire•12 days ago
SAN DIEGO, March 13, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that the company has concluded an FDA-approved feasibility study designed to assess the safety of the Aethlon Hemopurifier® in health-compromised individuals. The Hemopurifier is a first-in-class medical device that reduces the presence of circulating viruses in infected individuals. The technology is a first-line candidate defense against a broad-spectrum of viruses that are not addressed with antiviral drug therapies, including natural occurring pandemic threats and agents of bioterrorism. Additionally, the device provides a strategy to augment the benefit of proven antiviral drug regimens.
- PR Newswire•17 days ago
Aethlon Medical To Present At ROTH Capital Partners 29th Annual Growth Stock Conference On March 14, 2017
SAN DIEGO, March 8, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the ROTH Capital Partners 29th Annual Growth Stock ...
- PR Newswire•24 days ago
SAN DIEGO, March 1, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that the European Patent Office has granted European Patent Number 2591359, entitled "METHODS AND COMPOSITIONS ...
AEMD : Summary for AETHLON MEDICAL INC - Yahoo Finance
Aethlon Medical, Inc. (AEMD)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Ask||4.04 x 500|
|Day's Range||3.35 - 3.61|
|52 Week Range||3.10 - 9.09|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-3.86|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|